- Metastatic colorectal cancer:
- In combination with fluorouracil-based chemotherapy:
- Bolus-IFL (ie, irinotecan, 5-FU, leucovorin): IV 5mg/kg/dose every 2 weeks
- FOLFOX4 (ie, oxaliplatin, 5-FU, leucovorin): IV 10mg/kg/dose every 2 weeks
- In combination with fluorouracil-based chemotherapy:
-
- In combination with a fluoropyrimidine (eg, 5-FU, capecitabine) plus irinotecan or oxaliplatin-based chemotherapy: IV 5mg/kg every 2 weeks OR IV 7.5mg/kg every 3 weeks
- First-line in non-squamous non-small cell lung cancer:
- IV 15mg/kg/dose every 3 weeks
- Use in combination with carboplatin and paclitaxel
- For patients with unresectable, locally advanced, recurrent or metastatic disease
- Renal cell carcinoma:
- IV 10mg/kg every 2 weeks
- Used in combination with interferon alfa-2a
- Cervical cancer:
- IV 15mg/kg every 3 weeks
- Used in combination with regimens: paclitaxel and cisplatin or paclitaxel and topotecan
- For persistent, recurrent or metastatic cervical cancer
- Recurrent glioblastoma multiforme:
- IV 10mg/kg every 2 weeks
- Ovarian, fallopian tube or peritoneal cancer:
- Platinum-resistant:
- IV 10mg/kg every 2 weeks in combination with IV chemotherapy regimens of: paclitaxel, pegylated liposomal doxorubicin or topotecan weekly OR IV 15mg/kg IV every 3 weeks in combination with topotecan every 3 weeks
- Patients who have received no more than 2 prior chemotherapy regimens
- Platinum-resistant:
-
- Platinum-sensitive:
- IV 15mg/kg every 3 weeks in combination with carboplatin and paclitaxel for 6-8 cycles OR IV 15mg/kg every 3 weeks in combination with carboplatin and gemcitabine for 6-10 cycles then IV 15mg/kg every 3 weeks as a single agent until disease progression
- Platinum-sensitive:
- Treatment of stage III or IV disease following initial surgical resection:
- IV 15mg/kg every 3 weeks in combination with carboplatin and paclitaxel for up to 6 cycles followed by IV 15mg/kg every 3 weeks as a single agent for a total of up to 22 cycles or until disease progression, whichever occurs earlier
- First-line unresectable or metastatic hepatocellular carcinoma:
- IV 15 mg/kg on Day 1 (after administration of atezolizumab), PLUS atezolizumab IV 1,200mg/kg on Day 1
- Repeat every 3 weeks
- Continue until disease progression or unacceptable toxicity
- Neovascular age-related macular degeneration (Off-label):
- 25mg intravitreally every month
- May decrease to 1.25mg intravitreally PRN after 3 doses
Injection:
- 100 mg/4mL
- 400mg/16mL
- Withhold for at least 28 days before elective surgery
- Do not administer until at least 28 days after a major surgery and until adequate wound healing
VEGF inhibitor anticancer
It binds and inhibits vascular endothelial growth factor (VEGF), resulting in decreased angiogenesis, tumor growth and cancer progression
- Fatigue
- Diarrhea
- Nausea
- Hypertension
- Epistaxis
- Headache
- Arthralgia
- Dyspnea
- Stomatitis
- Pain
- Anorexia
- Dysphonia
- Proteinuria
- Muscular weakness
- Neutropenia
- Weight loss
- Cough
- Myalgia
- Hyperglycemia
- Back pain
- Thrombocytopenia
- Hypomagnesemia
- Abdominal pain
- Vomiting
- Rhinitis
- Dizziness
- Hyponatremia
- Increased creatine
- Exfoliative dermatitis
- Hypoalbuminemia
- Thromboembolism
- Mucositis
- Sinusitis
- Dysgeusia
- Xeroderma
- Rectal hemorrhage
- Lacrimation disorder
- Nasal septal perforation
- Hypersensitivity to components
- Breastfeeding during treatment and for 6 months after discontinuation (oncologic use)
- Ovarian cancer with recto-sigmoid or bowel involvement
- Uncontrolled hypertension
- Severe hemorrhage
- Recent hemoptysis
- GI perforation
- Fistula
- Unhealed surgical wound
- Major surgery with in prior 28 days
- Avoid treatment for at least 28 days before elective surgery
- Cidofovir
Drug Status
Availability | Prescription only |
Pregnancy | Category C |
Breastfeeding | Contraindicated |
Schedule | Not controlled |
BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
---|---|---|---|---|---|
Avastin | 100mg/4mL | Injection | 1’s | F. Hoffman-La Roche | Roche Kenya |
Avastin | 400mg/16mL | Injection | 1’s | F. Hoffman-La Roche | Roche Kenya |
Bevaas | 100mg/4mL | Injection | 1’s | Hetero Biopharma | Unisel Ltd |
Bevaas | 400mg/16mL | Injection | 1’s | Hetero Biopharma | Unisel Ltd |
Bevacizumab Amring | 400mg/16mL | Injection | 1’s | Amring Pharma | Prodigy Healthcare |
Bevacizumab Amring | 100mg/4mL | Injection | 1’s | Amring Pharma | Prodigy Healthcare |